FAQ/Help |
Calendar |
Search |
Today's Posts |
08-15-2021, 12:18 AM | #2 | ||
|
|||
Member
|
Dosing has now been completed in Annovis Bio's Phase 2a Trial of Posiphen (ANVS401).
PNT article: Dosing Finished in Phase 2a Trial of ANVS401 for Parkinson's, Alzheimer's This Phase 2a trial is described in the study record as a trial in two parts. The first part has 14 early PD patients and 14 early AD patients, taking either 80 mg daily of ANVS401 or placebo. Patient involvement in part 1 has been completed, and some interim results have been announced. The second part has 40 early PD patients taking 5 mg, 10 mg, 20 mg or 40 mg (no placebo). Patient involvement in part 2 has now also been completed. Some commentators regard the (early) release of interim data from part 1 as "drip feeding" results from an ongoing trial. For example, see this SoPD blog post comment from Simon: Monthly Research Review – June 2021 – The Science of Parkinson's Personally, I'm giving them the benefit of the doubt. |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Phase 1/2a Trial Recruiting ALS Patients to Test AstroRx, Potential New Stem Cell The | ALS News & Research | |||
Phase III Recruiting: Effects of Coenzyme Q10 (CoQ) in PD | Parkinson's Disease Clinical Trials | |||
Phase III Recruiting: Effects of Coenzyme Q10 (CoQ) in PD | Parkinson's Disease | |||
GAD recruiting - another sham surgery trial | Parkinson's Disease | |||
Neurologix Phase II recruiting...GAD | Parkinson's Disease |